1. Home
  2. ARVN vs ACP Comparison

ARVN vs ACP Comparison

Compare ARVN & ACP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arvinas Inc.

ARVN

Arvinas Inc.

N/A

Current Price

$6.79

Market Cap

600.2M

Sector

Health Care

ML Signal

N/A

Logo abrdn Income Credit Strategies Fund

ACP

abrdn Income Credit Strategies Fund

N/A

Current Price

$4.29

Market Cap

637.4M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
ARVN
ACP
Founded
2015
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
600.2M
637.4M
IPO Year
2018
2010

Fundamental Metrics

Financial Performance
Metric
ARVN
ACP
Price
$6.79
$4.29
Analyst Decision
Buy
Analyst Count
15
0
Target Price
★ $14.00
N/A
AVG Volume (30 Days)
859.5K
★ 968.5K
Earning Date
11-03-2026
01-01-0001
Dividend Yield
N/A
★ 17.79%
EPS Growth
★ 58.84
N/A
EPS
★ 0.88
N/A
Revenue
★ $262,600,000.00
N/A
Revenue This Year
$5.67
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$7.78
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$6.33
$4.12
52 Week High
$14.22
$5.76

Technical Indicators

Market Signals
Indicator
ARVN
ACP
Relative Strength Index (RSI) 41.87 46.37
Support Level $6.74 $4.12
Resistance Level $7.85 $4.49
Average True Range (ATR) 0.47 0.08
MACD -0.03 0.02
Stochastic Oscillator 27.06 62.74

Price Performance

Historical Comparison
ARVN
ACP

About ARVN Arvinas Inc.

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

About ACP abrdn Income Credit Strategies Fund

abrdn Income Credit Strategies Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income with a secondary objective of capital appreciation. It predominantly invests in debt and loan instruments of issues that operate in a variety of industries and geographic regions.

Share on Social Networks: